Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs PPG Industries, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.07 (market cap $29.60B), while PPG Industries, Inc. trades at $114.85 (market cap $25.82B). The key difference: Alnylam Pharmaceuticals, Inc. and PPG Industries, Inc. are close in size by market cap, and PPG Industries, Inc. pays a 2.55% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PPG | |
|---|---|---|
Market Cap | $29.60B | $25.82B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $131.56 |
52-Week Low | $205.48 | $94.34 |
Enterprise Value | $27.56B | $31.69B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
PPG Industries trades at $114.90, down 0.49% on the day, with mixed technical signals showing neutral momentum. The company maintains solid fundamentals with $15.88B in 2025 revenue, 9.57% net margin, and strong cash flow generation. Recent Q2 2026 earnings of $2.23 per share slightly missed expectations despite 7% sales growth. Analyst sentiment remains positive with 55% buy ratings and a $129.17 consensus price target representing 12% upside potential.
PPG offers attractive valuation with 16.67 P/E and dividend growth potential, but faces margin pressure from raw material costs. The stock presents a balanced opportunity for income and value investors, though macroeconomic headwinds and competitive pressures require monitoring. The recent dividend increase to $0.74 per share reinforces management's confidence in long-term cash flow stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
